爵士製藥 JAZZ 深 滬
等待開盤 11-26 09:30:00 美东时间
180.05
-0.850
-0.47%
華盛通- 最 高182.75
- 今 開181.24
- 成交量 112.46万股
- 最 低 178.01
- 昨 收 180.90
- 總市值 108.95亿
- 52周最高 182.99
- 市盈率 靜 20.82
- 換手率 1.86%
- 52周最低 95.49
- 委 比 -79.94%
- 總股本 6051.10万
- 歷史最高 194.73
- 量 比 0.50
- 振 幅 2.62%
- 歷史最低 31.87
- 每 手 1
- 風險率 14.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
华尔街顶级分析师最新观点：缤客、Carvana获评级上调
如今，华尔街最受关注、且能影响市场走势的研究评级观点已汇总于一处。以下是由 The Fly 整理的今日投资者需关注的研究评级动态。 五大评级上调案例： ...
11-25 00:32
UBS Downgrades Jazz Pharmaceuticals to Neutral, Raises Price Target to $188
UBS analyst Ashwani Verma downgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) from Buy to Neutral and raises the price target from $163 to $188.
11-24 21:29
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. announced that its management will participate in two upcoming investor conferences: the Evercore 8th Annual Healthcare Conference on December 2, 2025, and the Citi 2025 Global Healthcare Conference on December 3, 2025, both in Miami, FL. Zymeworks is a global biotechnology company developing innovative biotherapeutics for treating difficult-to-treat diseases such as ca...
11-24 11:00
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
Zymeworks shifts to a royalty-driven business model
Zymeworks (ZYME) on Tuesday announced plans to focus on a royalty-driven growth model backed by its internal R&D engine and licensing arrangements with companies such as Johnson & Johnson (JNJ). The m...
11-19 01:24
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. announced the appointment of Scott Platshon as Acting Chief Investment Officer. Platshon will manage future cash flows from Ziihera® and other healthcare assets, while overseeing Zymeworks’ asset aggregation strategy. He steps down from the Board of Directors but continues as a Partner at EcoR1 Capital. Platshon’s expertise and knowledge of Zymeworks’ strategic objectiv...
11-18 06:01
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points o...
11-18 00:39
Jazz, Zymeworks’ Ziihera trial shows significant PFS improvement, shares rally
Zymeworks (ZYME) on Monday reported positive topline results from its Phase 3 trial of Ziihera, with or without Tevimbra, as a first-line treatment for HER2-positive advanced gastroesophageal cancers,...
11-17 20:13
